Arbutus Biopharma
ABUS
39 hedge funds and large institutions have $97.6M invested in Arbutus Biopharma in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 18 closing their positions.
40% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $1.05M
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
22% less funds holding
Funds holding: 50 → 39 (-11)
44% less capital invested
Capital invested by funds: $174M → $97.6M (-$76.7M)
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$3.65M |
| 2 |
Renaissance Technologies
New York
|
+$1.78M |
| 3 |
Millennium Management
New York
|
+$1.75M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$1.58M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$5.01M |
| 2 |
Morgan Stanley
New York
|
-$3.18M |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.92M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.14M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
51
Atika Capital Management
New York
| – | -$279K | -13,000 | Closed |
|
52
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$160K | -11,320 | Closed |
|
|
OAM
53
Orinda Asset Management
Lafayette,
California
| – | -$162K | -7,530 | Closed |
|
|
MAA
54
Managed Account Advisors
Jersey City,
New Jersey
| – | -$35K | -1,607 | Closed |
|
|
QT
55
Quantbot Technologies
New York
| – | -$25K | -1,200 | Closed |
|
|
VIA
56
Vantage Investment Advisors
State College,
Pennsylvania
| – | -$5K | -250 | Closed |
|
57
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$241 | +17 | New |
|
ABUS Hedge Fund Activity: Q2 2014 in Review
39 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2014, worth a combined $97.6M — down 44% from $174M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ABUS and 7 opened new positions — a net loss of 11 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was AllianceBernstein, adding an estimated $3.65M. The largest seller was Systematic Financial Management, exiting entirely with an estimated $5.01M sold.
- 39 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2014, down from 50 in Q1 2014.
- Funds reported $97.6M of Arbutus Biopharma stock for Q2 2014, down 44% quarter-over-quarter.
- 7 funds opened new Arbutus Biopharma positions in Q2 2014 and 18 closed out, a net change of -11 holders.
- The largest Arbutus Biopharma buyer in Q2 2014 was AllianceBernstein, an estimated $3.65M added.
- The largest Arbutus Biopharma seller in Q2 2014 was Systematic Financial Management, an estimated $5.01M sold.
Based on aggregated 13F filings for Q2 2014.